Kornimate/medical-research-clean huggingface dataset:
allogeneic hematopoietic stem cell transplant for patients with primary immune deficiencies

Conditions: SCID; Omenn's Syndrome; Reticular Dysgenesis; Wiskott-Aldrich Syndrome; Bare Lymphocyte Syndrome; Common Variable Immunodeficiency; Chronic Granulomatous Disease; CD40 Ligand Deficiency; Hyper IgM Syndrome; X-linked Lymphoproliferative Disease; Hemophagocytic Lymphohistiocytosis; Griscelli Syndrome; Chediak-Higashi Syndrome; Langerhan's Cell Histiocytosis

Summary: this is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (hsct) in patients with primary immune deficiencies.

based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans: arm a: fully myeloablative preparative regimen, arm b: reduced toxicity ablative preparative regimen, arm c: reduced intensity conditioning, arm d: no preparative regimen

Eligibility criteria:
inclusion criteria: * diagnosis of immunodeficiency or histiocytic disorder including the following: * severe combined immunodeficiency (scid - all variants) * second bone marrow transplant (bmt) for scid (after graft rejection) * omenn's syndrome * reticular dysgenesis * wiskott-aldrich syndrome * major histocompatibility complex (mhc) class ii deficiency (bare lymphocyte syndrome) * hyper igm syndrome (cd40 ligand deficiency) * common variable immunodeficiency (cvid) with severe phenotype * chronic granulomatous disease (cgd) * other severe combined immune deficiencies (cid) * hemophagocytic lymphohistiocytosis (hlh) * x-linked lymphoproliferative disease (xlp) * chediak-higashi syndrome (chs) * griscelli syndrome * langerhans cell histiocytosis (lch) * acceptable stem cell sources include: * hla identical or 1 antigen matched sibling donor eligible to donate bone marrow * hla identical or up to a 1 antigen mismatched unrelated bm donor * sibling donor cord blood with acceptable hla match and cell dose as per current institutional standards * single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum cell dose of \>5 x 10\^7 nucleated cells/kg as per current institutional guidelines * double unrelated umbilical cord blood units that are: * up to 2 antigen mismatched to the patient * up to 2 antigen mismatched to each other * minimum cell dose of at least one single unit must be ≥ 3.5 x 10\^7 nucleated cells/kg * combined dose of both units must provide a total cell dose of ≥ 5 x 10\^7 nucleated cells/kg * age: 0 to 50 years * adequate organ function and performance status. exclusion criteria * pregnant or breastfeeding * active, uncontrolled infection and/or hiv positive * acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy

Keywords: immunodeficiency disorder histiocytic disorder
specially designed eating plates effects on food intake in normal weight and overweight children

Conditions: Obesity

Summary: previous studies demonstrated that children served themselves more food when using larger plates and bowels. the purpose of this study is to evaluate if self-served portions and caloric intake in normal weight and overweight children will be influenced by a specially designed eating plates compared to similar size normal plates.

40 normal weight and 40 overweight kindergarden and elementary school children will participate in this study. anthropometric measurements: weight, height, bmi and bmi percentiles will be measured and calculated for each participant. the participants will take part in two non-exercise activities at the 'sport and health center for children and adolescence'. at the end of each activity, a lunch buffet that contains all food ingredients will be served. during one meeting the children will be handed a regular plate and at the second meeting they will be handed a specially designed plate (with marking of the recommended meal composition and portion). the amount and composition of food on the plates will be assessed by weighing and photography before and after eating and analysed to report macronutrient consumption by a dietitian. the meetings for normal weight children will be separated from the overweight children.

Eligibility criteria:
inclusion criteria: * over weight / obese children * normal weight children exclusion criteria: * organic disease that cause obesity * underweight children (bmi percentiles \< 5)

Keywords: childhood obesity plate food consumption
ultrasonography biofeedback for diaphragm training in athletes with lumbo-pelvic pain

Conditions: Ultrasonography; Low Back Pain

Summary: objective: to determine the effectiveness of diaphragm biofeedback reeducation by ultrasonography in conjunction with high-intensity inspiratory muscle training versus isolated high-intensity inspiratory muscle training in athletes with lumbo-pelvic pain. methods: a single blinded randomized clinical trial will be carried out. a total sample of 80 athletes with lumbo-pelvic pain will be recruited and randomized into 2 groups: one group will be treated by isolated high-intensity inspiratory muscle training during 8 weeks, and another group will be treated with diaphragm biofeedback reeducation by ultrasonography during 6 weeks in conjunction with high-intensity inspiratory muscle training during 8 weeks. outcome measurements will be diaphragm muscle thickness evaluated by ultrasonography (main outcome measurement), pain intensity, pressure pain threshold, disability, quality of life and respiratory parameters by spirometry, which will be assessed before and after intervention.


Eligibility criteria:
inclusion criteria: * athletes with non-specific lumbopelvic pain during 6 weeks exclusion criteria: * neural disorders * systemic disorders * cognitive disorders
caspofungin maximum tolerated dose in patients with invasive aspergillosis

Conditions: Invasive Aspergillosis

Summary: this study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.

due to its efficacy and a broad antifungal spectrum against relevant fungal pathogens, lack of cross-resistance to azoles and amphotericin b, documented efficacy against human aspergillus infections, favorable pharmacokinetic properties, and excellent tolerability according to the current data, caspofungin is a highly promising candidate for improving the results of treatment of invasive fungal infections. preclinical and clinical data indicate a dose dependent antifungal efficacy of caspofungin as well as of other echinocandins such as micafungin and anidulafungin. thus it appears reasonable to investigate the impact of higher doses of caspofungin to improve the results already achieved with this component so far. the maximum tolerated dose (mtd) of caspofungin and the distribution of the drug in patients following administration of doses of 70 mg or more are not yet known. we therefore investigate the safety, tolerability and pharmacokinetics of caspofungin in rising doses in a dose escalation study in adult patients with proven or probable invasive aspergillosis.

Eligibility criteria:
inclusion criteria: * immunocompromised due to hematologic malignancies, bone marrow failure syndromes, hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, hiv infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections. * evidence of proven or probable invasive aspergillosis, by modified eortc criteria exclusion criteria: * concomitant other systemic antifungal agents are not permitted on study. * chronic invasive fungal infection, defined as signs/symptoms of invasive fungal infection present for \> 4 weeks preceding entry into study * prior systemic therapy of ≥ 4 days with any polyene anti-fungal agent within 14 days of study enrollment * prior systemic therapy of ≥ 4 days with non-polyenes for the current, documented ifi.

Keywords: aspergillosis caspofungin maximum tolerated dose
community acquired sepsis cohort

Conditions: Severe Septic Syndrome; Septic Shock

Summary: the aim of this project is to constitute a prospective cohort of all the patients presenting to the adult emergencies of the university hospital centre (chu) of rennes for a septic syndrome of community origin.

severe septic syndrome (ssg) and septic shock (cs) are two frequent and serious complications of infectious diseases. in this context, the optimization of the management of septic patients from their reception in the emergency services must be a priority. however there are no predictors of progression or severity in patients admitted to emergencies despite the recommendations emphasizing the need for screening and early therapeutic management. many scores have been proposed for intensive care unit but they remain difficult to extrapolate to other services because they are very comprehensive and require information that is difficult to obtain for emergency physicians.

Eligibility criteria:
inclusion criteria: * patient older than 18 years old * patient hospitalized during the study period for community infectious diseases at the chu of rennes exclusion criteria: * written objection from the patient to the computer processing of his data * pregnant women * persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty
natural killer cells functions, tumoral escape to immune system and regulation of natural cytotoxixity receptors in haematological malignancies

Conditions: Leukemia

Summary: the nk cells participate in the innate immunity against infectious agents or transformed cells that are recognized as "no self" by the absent, weak or abnormal expression of human leukocyte antigen (hla) class i molecules. according to the "missing self hypothesis", a negative signal is delivered to nk cells when their inhibitory receptors are engaged by the specific hla class i molecules. nk activation requires a positive signal delivered by the engagement of activating receptors, more particularly of the "natural cytotoxicity receptors" or ncrs who are directly involved in the natural cytotoxicity of natural killer. the activating receptors include nkp46, nkp44 and nkp30, also called ncr 1, 2 and 3 respectively. nkp46 and nkp30 are constitutively expressed on the surface of the nk, the expression of nkp44 is observed only after activation of cells nk. nk cells from most (80%) healthy donors express a high quantity of ncr on their surface, corresponding to the ncrbright phenotype while only 20 % present the ncrdull phenotype. in sharp contrast, most patients (80%) having leukaemia have the ncrdull while only 20 % patients have the ncrbright phenotype. the culture of nk from healthy donors ( ncrbright) with leukaemic cells result in decreased expression of the nkp30 while there is no difference on expression if these same nk are cultivated with cells from healthy donors. moreover, study of aml patients showed that the ncrdull phenotype was acquired during leukemia development because it was observed its complete (for nkp46) or partial (for nkp30) reversibility in patients achieving complete remission (cr). reversibility of the ncrdull phenotype after cr suggested that leukemia cells might be involved in ncr down-regulation. in line with these observations, we aim to study the mechanism of ncr down-regulation by cultivating nk ncrbright from healthy donors with leukaemic cells or healthy haematopoietic cells, in order to observe the appearance of the ncrdull phenotype and verify by qpcr if this down-regulation is transcriptionnal. if this hypothesis is be verified, we will study the regulation of ncr by focusing on the implication of genes ncr transcription factors via bio-informatic analysis of putative transcription factors fixation sequences in the promoters of these genes, followed by the verification of the capacity of identified sequences to bind transcription factors. ultimately, we will verify the real implications of these transcription factors by studying the effect of their silencing by rna interference experiments.


Eligibility criteria:
inclusion criteria: * grown-up patients having a leukaemia aigue myéloïde (lam) in the diagnosis, whatever is lam's subcategory (fab or cytogenetics). * the patients that must be informed at the same time, willing, and having given their agreement in writing. exclusion criteria: * refusal of the patient. * phénotypage nk not corresponding to the quotas dull / bright required.
derivation of tumor specific hybridomas

Conditions: Glioblastoma

Summary: this is a non-randomized, open-label study in patients with newly diagnosed glioblastoma to determine the ability to generate human hybridomas from lymph nodes draining an autologous tumor vaccine injection and demonstrate that the hybridomas secrete glioblastoma-specific antibodies.

the intradermal vaccine will be injected 20cm in the anterior thigh. vaccination will be done twice and separated by one week. the first vaccination will be performed approximately 2 weeks after surgery. approximately one week after the second vaccination one or two vaccine-draining lymph node(s) will be removed. the lymph node(s) will be identified using sn technology. one or two lymph node(s) will be removed. lymph nodes will be processed for recovery of b cells and formation of hybridomas.

Eligibility criteria:
inclusion criteria: * patients with confirmed new diagnosis of glioblastoma and who have a yield of at least 8x10(7) tumor cells obtained at the time of surgery * age \> 18 years * kps score of greater than or equal to 70 * adequate bone marrow as evidenced by: absolute lymphocyte count \> 1,000/ul platelet count \> 50,000/ul * adequate renal function as evidenced by serum creatinine \< 2.0 * patients must be able to read, understand and provide informed consent to participate in the trial. * patients of childbearing potential must agree to use an effective form of contraception during the study and for 90 days following vaccination (an effective form of contraception is an oral contraceptive or a double barrier method) exclusion criteria: a patient may not be enrolled in the trial if any of the following criteria are met: * patients receiving dexamethasone \> 8 mg/day during the week before vaccination. * patients who are pregnant or lactating * patients with active second malignancy. * any other medical conditions, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

Keywords: immunotherapy, cancer vaccine, glioblastoma, hybridoma
comparing the effectiveness of oral versus intravenous pain medicine for suction curettage (d&c)

Conditions: Undesired Pregnancy

Summary: the main objective of this study is to determine the equivalency of oral conscious sedation and intravenous conscious sedation for first trimester surgical abortion. we hypothesize that oral conscious sedation will be equivalent to intravenous conscious sedation for pain control. additional objectives include describing subject satisfaction with each method of pain control and characteristics of each method such as side effect profile, recovery room time, and postoperative pain.

the main objective of this study is to determine the equivalency of oral conscious sedation (oxycodone 10mg po plus lorazepam 1mg sl) and intravenous conscious sedation (fentanyl 100 µg plus midazolam 2mg) for first trimester surgical abortion. we hypothesize that oral conscious sedation will be equivalent to intravenous conscious sedation as defined by ± 1 point on a 21-point pain scale. subsidiary objectives include describing subject satisfaction with each method of pain control and characteristics of each method such as side effect profile, recovery room time, and postoperative pain.

Eligibility criteria:
inclusion criteria: * age 18 or older. * undesired pregnancy between 6 0/7-12 6/7 weeks gestation. * has already signed consent for pregnancy termination. * eligible for iv sedation per clinic protocol. exclusion criteria: * under 120 lbs. * allergies to any of the drugs being studied. * chronic narcotics, barbiturates or benzodiazepine use within the past year. * history of iv drug use within the last year. * inability to give informed consent. * does not speak english or spanish and does not have translator for all study procedures * previously participated in study
a comparative evaluation of a mps dressing and a cmc dressing on subjects with lower extremity venous ulcers

Conditions: Venous Leg Ulcer

Summary: venous leg ulcers are lower extremity ulcers that develop due to sustained venous hypertension resulting from chronic venous insufficiency. varicose veins, deep vein thrombosis, poor calf muscle function, arterio-venous fistulae, obesity and history of leg fracture are some of the risk factors for venous ulceration. numerous dressing types exist to treat these ulcers. this study will compare a marine polysaccharide (mps) dressing to a carboxymethylcellulose dressing to determine which dressing better manages these wounds with regard to wound size and periwound skin condition. subjects will be randomized to receive either mps-ag dressing or cmc-ag dressing.


Eligibility criteria:
inclusion criteria: * subject is able and willing to comply with requirements of this trial protocol * voluntarily signed informed consent before any trial related procedures are performed * subjects must be able to communicate effectively with study personnel * subject has lower extremity venous ulcer wound, as determined by site pi. * subject has adequate circulation as determined by biphasic or triphasic doppler waveform, consistent with adequate blood flow, within three months prior to study enrollment. if monophasic on exam, then non-invasive tests must display ankle brachial index over 0.8 and no worse than mild disease on segmental pressures. * subjects should not be allergic to silver (ag). * size of subject's wound is between 1 squared centimeter and 100 squared centimeters. * duration of subject's wound is less than 52 weeks. exclusion criteria: * subjects who are pregnant, nursing, or planning to become pregnant during the course of the study. * subjects who have known allergies to any ingredient(s) in the clinical products used in this study. * subjects who do not wish to use products derived from shellfish. * subjects with substance use disorder. * subjects with active infection or currently receiving antibiotic treatment. * subjects who are currently enrolled in another research study which includes investigational treatment and/or medication. * subjects judged by the investigator or sub-investigator to be inappropriate as a subject of this study. * subject has previous or current systemic disease(s) which, in the judgement of the site pi, is likely to interfere with the study. however, subjects with well-controlled diabetes mellitus (hba1c \< 8.5) shall be permitted.
tranexamic acid and epistaxis in hereditary hemorrhagic telangiectasia (hht)

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: hereditary hemorrhagic telangiectasia (hht, rendu-osler-weber syndrome) is associated with frequent nosebleeds in the majority of cases. several reports in the literature support the use of antifibrinolytics like tranexamic acid to reduce nosebleeds. the objectives of the study are to test if tranexamic acid taken orally can 1. improve anemia (lead to an increased hemoglobin level) 2. reduce nosebleeds.


Eligibility criteria:
inclusion criteria: * hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated. exclusion criteria: * pregnant, * minor, * had an increased risk of thrombotic events (history or signs of cerebrovascular events, cardiac arrhythmias, biochemically increased coagulation parameters), * renal insufficiency, * a history of massive hematuria or defects of color vision.

Keywords: hereditary hemorrhagic telangiectasia rendu-osler-weber syndrome epistaxis nosebleeds anemia tranexamic acid antifibrinolytics
pharmacists' interventions to improve blood pressure in chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: the aims of the study were to determine whether pharmacists' interventions combining patient home-based self-measured bp monitoring improve blood pressure reduction and control compared with usual care in chronic kidney disease (ckd) patients

this is a prospective randomized two-group pharmacist-led interventional study that was conducted in two public nephrology clinics. the study involved the introduction of pharmaceutical care to improve blood pressure and adherence to the prescribed medications among patients with chronic kidney disease (ckd). recruited patients were randomly divided into two groups; the intervention group and the control group, with baseline evaluation of outcomes measured. the control group was provided with usual care. an intervention group was provided in addition to the usual care, face-to-face education on ckd, hypertension as a co-morbidity and its management, and antihypertensive medication adherence at baseline (group education), 6 months and 12 months (individualized according to each patient's needs), ckd patient educational infographic leaflet at baseline, a calibrated sphygmomanometer digital blood pressure monitor (chidalex®) for home-based self-measured bp monitoring, a bp logbook at baseline for the recording of blood pressure values daily and hands-on training on bp self-measurement. also, antihypertensive medication adherence and home-based self-measured bp monitoring, reminder cell phone text messages were sent biweekly throughout the trial period, while phone-in inquiries from the participants and phone-out reinforcement interventions were utilized throughout the trial period. both groups were followed for a period of 12 months.

Eligibility criteria:
inclusion criteria: * ckd stages 1 - 4, * voluntary written informed consent, * willingness to abide by the rules of trial, and * availability during the trial duration exclusion criteria: * patients with acute renal failure, * ckd stage 5, * pregnant or lactating women, * post-renal transplant patients, * patients with hiv infection, * critically ill patients or patients known to have cognitive impairment.

Keywords: blood pressure chronic kidney disease home blood pressure self-monitoring nigeria pre-dialysis pharmacists' interventions